Leállítva2/3. fázis
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
A legfontosabb adatok
- Ki végzi
- Staidson (Beijing) Biopharmaceuticals Co., Ltd
- Hol
- Banglades, India, Indonézia, Kína és Spanyolország12 helyszín, 5 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Leállítva
- Fázis
- 2/3. fázis
- Résztvevők
- 369 fő vett részt
- Kezdés
- 2020. júl. 23.
- Befejezés
- 2024. márc. 26.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoport
- A vizsgált kezelések
- BDB-001 Injection
- Conventional treatment
- A regiszteradat frissítve
- 2024. május 22.
- Miért állt le
- Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
Ki vehet részt
- Életkor
- 18 év – 80 év
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 13 feltétel megnézéseKevesebb
Ki vehet részt
- 18 years old ≤ age ≤ 80 years old, both men or women
- Confirmed SARS-CoV-2 infection, and meet at least one of the following criteria:; Confirmed severe COVID-19 in no more than 5 days who meets any of the following criteria:; Respiratory distress, RR ≥ 30 times/min; Finger oxygen saturation (SpO2) ≤93% in resting state(room air); Arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) ≤ 300 mmHg (1 mmHg = 0.133kpa) in supine position; Pulmonary imaging shows lesion progression > 50% within 24-48 hours; Symptoms,signs or chest imaging indicates ALI/ARDS
- Requiring a mask oxygen therapy,high-flow nasal cannula oxygen therapy(HFNC)
- The informed consent form signed
Ki nem vehet részt
- Subjects on current treatment with a complement inhibitor such as eculizumab within 1 month before randomization
- A subject has used the following drugs within 2 weeks prior to screening procedures:; Calcineurin inhibitors (e.g., ciclosporin, tacrolimus, etc.); Proliferation inhibitors (e.g., everolimus, sirolimus, etc.); Anti-metabolic drugs (e.g., mycophenolate mofetil, mycophenolate, purine sulphate, etc.); Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF)/recombinant human granulocyte colony stimulating factor (rhG-CSF)
- Subjects already progressed into critically severe COVID-19 Critical severe standards refer to FDA guidelines,as shown in Appendix 4 or sepsis and sepsis shock
- Subjects with hypersensitivity history to any ingredient contained in the drug
- Concomitant with the following situation:severe lung disease such as chronic obstructive pulmonary disease (moderate to severe type), lung cancers, active tuberculosis; severe cardiovascular and cerebrovascular disease: unstable angina pectoris, myocardial infarction, postcardiac surgery, cardiac function ≥ grade 3 (NYHA Classification), or had undergone heart surgery within 6 months before randomization; severe liver diseases (e.g. Child-Pugh score ≥ grade C); severe kidney diseases, such as renal insufficiency (GFR ≤ 15 mL/min/1.73m\^2); immune deficiencies or immune-related diseases : including organ or bone marrow transplantation, some autoimmune diseases, IgG4-related diseases, allergic alveolitis, vasculitis; malignancies
- Subject who meets any of the following criteria will be excluded from the trial:
- Pregnant or lactating woman
- Subjects who have participated in other interventional clinical trials in the last 3 months or during this trial
- Any other circumstances that the investigator considers inappropriate for the participation in this study
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
5 országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
This multi-center, open, randomized study will evaluate the efficacy and safety of BDB-001 injection in severe COVID-19 with severe pneumonia, or acute lung injury/acute respiratory distress syndrome. Patients will be randomized to two treatment arms (Arm A: Conventional treatment + BDB-001; Arm B: Conventional treatment alone).
A vizsgálat 2 csoportja
- Treatment groupA vizsgált kezelés
Kezelés: BDB-001 Injection
- Control groupA vizsgált kezelés
Kezelés: Conventional treatment
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- A Multi-center, Open-label, Randomized Parallel Controlled Evaluation on the Efficacy and Safety of BDB-001 Injection in the Treatment of Progressive Severe COVID-19 in Phase II/III
- A regiszteradat frissítve
- 2024. május 22.